Search clinical trials for: Imatinib Mesylate (Gleevec)

Total 2818 results

Fujian Cancer Hospital

Unknown

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Locally Advanced Non-Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

PLATFORM Study of Precision Medicine for Rare Tumors

Rare Tumor
The First Affiliated Hospital of Xiamen University

Unknown

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Locally Advanced or Metastatic Gastric Adenocarcinoma

China
Heidelberg University

Completed

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

Germany, Switzerland
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia

Leukemia

United States
Sun Yat-sen University

Completed

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Ovarian Cancer

China
Fujian Medical University

Active, not recruiting

Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Advanced Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Advanced Solid Tumor

China
IlDong Pharmaceutical Co Ltd

Completed

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

Healthy

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)

Gastrointestinal Stromal Tumors

United States, Australia, Germany, Spain, Korea, Republic of, Canada, France, Poland, Austria, Netherlands, Italy, Czech Republic, Switzerland
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Solid Tumor

China
Beijing 302 Hospital

Not yet recruiting

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

HER2-negative Breast Cancer Brain Metastases

China
Zhou Fuxiang
Hubei Cancer Hospital; Henan Provincial People's Hospital; Huangshi Central Hospital...

Recruiting

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Zhou Fuxiang
Hubei Cancer Hospital; Shiyan Taihe Hospital; Huangshi Central Hospital, China; Xianning Central Hospital and other collaborators

Unknown

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Small-cell Lung Cancer
Assistance Publique - Hôpitaux de Paris
Group for Research in Adult Acute Lymphoblastic Leukemia

Completed

Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults

Leukemia, Lymphocytic

France
Fujian Cancer Hospital

Not yet recruiting

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Completed

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

China
Peking University

Recruiting

Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach

Gastric Cancer

China
CStone Pharmaceuticals

Recruiting

Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

Gastrointestinal Stromal Tumors

China
China Medical University, China

Unknown

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

Advanced Gastric Cancer

China
Fujian Medical University

Not yet recruiting

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Locally Advanced Gastric Cancer

China
Peking University Third Hospital

Unknown

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
University of Bologna
Novartis; Schering-Plough

Terminated

Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)

Chronic Myeloid Leukemia
Australasian Leukaemia and Lymphoma Group
Merck Sharp & Dohme LLC; Novartis Pharmaceuticals

Unknown

Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PInNACLe)

Chronic Myeloid Leukaemia

Australia
Peking University Cancer Hospital & Institute
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

A Clinical Study of Puesta Mesylate for Injection in Patients With Solid Tumors

Advanced Solid Tumor

China
University of Jena
Novartis Pharmaceuticals; Ludwig-Maximilians - University of Munich

Active, not recruiting

Frontline Asciminib Combination in Chronic Phase CML (CMLXI)

Chronic Myeloid Leukemia

Germany
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

Soft Tissue Sarcoma

China
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hematologic Diseases | Chronic Myelogenous Leukemia | CML | Leukemia, Myeloid Chronic

Taiwan, Italy, Spain, United Kingdom, Germany, United States, Korea, Republic of, France, Russian Federation, Canada, Denmark, Poland, Portugal, Austria, Czechia
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

China
The First Affiliated Hospital of Xiamen University

Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma

China
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Merz Pharmaceuticals GmbH

Terminated

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Multiple Sclerosis | Nystagmus, Congenital | Nystagmus, Acquired

United Kingdom
Merz Pharmaceuticals GmbH

Completed

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Healthy

Germany
Nanjing First Hospital, Nanjing Medical University

Enrolling by invitation

Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.

Main Heading (Descriptor) Terms

China
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Assistance Publique - Hôpitaux de Paris

Completed

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive (AFR07)

Blast Crisis | Philadelphia Chromosome | Leukemia, Lymphocytic, Acute | Leukemia, Myeloid, Chronic

France
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Gastric Cancer

China

3

Subscribe